<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640209</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 18415, 823584</org_study_id>
    <nct_id>NCT02640209</nct_id>
  </id_info>
  <brief_title>Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)</brief_title>
  <official_title>Pilot Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART19) in Combination With Ibrutinib in Patients With Relapsed or Refractory CD19+ CLL or SLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label pilot study to determine safety and efficacy of CART-19 cells in combination with&#xD;
      ibrutinib. The target dose will be 1-5x10xE8 CART-19 transduced cells administered via split&#xD;
      dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3. 15 evaluable subjects (adults) with&#xD;
      relapsed or refractory CLL/SLL who have achieved partial response or stable disease on&#xD;
      ibrutinib therapy will be eligible to receive CART-19 therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study is terminated due to administrative reasons.&#xD;
  </why_stopped>
  <start_date type="Actual">January 29, 2016</start_date>
  <completion_date type="Actual">July 16, 2019</completion_date>
  <primary_completion_date type="Actual">October 15, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>26 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART 19</intervention_name>
    <description>The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented CD19+ CLL or SLL&#xD;
&#xD;
          -  Successful test expansion -cells (as described in Section 6.1)&#xD;
&#xD;
          -  Patients must have failed at least 1 prior regimen before Ibrutinib (not including&#xD;
             single agent rituximab or single agent corticosteroids)&#xD;
&#xD;
             a. Note: Any relapse after prior autologous SCT will make the patient eligible&#xD;
             regardless of other prior therapy.&#xD;
&#xD;
          -  Patients must be currently receiving ibrutinib for at least 6 months prior to&#xD;
             enrollment in the study and:&#xD;
&#xD;
               1. Not experiencing any ≥ grade 2 non-hematologic ibrutinib-related toxicity&#xD;
&#xD;
               2. The best response to ibrutinib therapy must not have exceeded partial response or&#xD;
                  stable disease (i.e. no CR or CRi)&#xD;
&#xD;
               3. Note: Patients carrying a deletion at chromosome 17p (i.e. del[17p]), and/or&#xD;
                  TP53, BTK, and at the PLCγ2 loci mutations, will be eligible if they are&#xD;
                  receiving frontline therapy with ibrutinib.&#xD;
&#xD;
          -  ECOG Performance status 0 or 1&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Adequate organ system function including:&#xD;
&#xD;
               1. Creatinine &lt; 1.6 mg/dl&#xD;
&#xD;
               2. ALT/AST &lt; 3x upper limit of normal&#xD;
&#xD;
               3. Total Bilirubin &lt;2.0 mg/dl with the exception of patients with Gilbert syndrome;&#xD;
                  patients with Gilbert syndrome may be included if their total bilirubin is ≥ 3.0&#xD;
                  x ULN and direct bilirubin ≤ 1.5 x ULN.&#xD;
&#xD;
          -  Patients with relapsed disease after prior allogeneic SCT (myeloablative or&#xD;
             nonmyeloablative) will be eligible if they meet all other inclusion criteria and:&#xD;
&#xD;
               1. Have no active GVHD and require no immunosuppression&#xD;
&#xD;
               2. Are more than 6 months from transplant&#xD;
&#xD;
          -  No contraindications for leukapheresis&#xD;
&#xD;
          -  Left Ventricular Ejection fraction &gt;40%&#xD;
&#xD;
          -  Gives voluntary informed consent&#xD;
&#xD;
          -  Subjects of reproductive potential must agree to use acceptable birth control methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CLL patients with known or suspected transformed disease (i.e. Richter's&#xD;
             transformation). Note: biopsy proven absence of transformation is not required.&#xD;
&#xD;
          -  Pregnant or lactating women. The safety of this therapy on unborn children is not&#xD;
             known. Female study participants of reproductive potential must have a negative serum&#xD;
             or urine pregnancy test performed within 48 hours before infusion.&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          -  Concurrent use of systemic steroids or chronic use of immunosuppressant medications.&#xD;
             Recent or current use of inhaled steroids is not exclusionary.&#xD;
&#xD;
          -  Any uncontrolled active medical disorder that would preclude participation as&#xD;
             outlined.&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Patients with active CNS involvement with malignancy. Patients with prior CNS disease&#xD;
             that has been effectively treated will be eligible providing treatment was &gt;4 weeks&#xD;
             before enrollment.&#xD;
&#xD;
          -  Class III/IV cardiovascular disability according to the New York Heart Association&#xD;
             Classification.&#xD;
&#xD;
          -  Subjects with clinically apparent arrhythmia or arrhythmias who are not stable on&#xD;
             medical management within two weeks of enrollment.&#xD;
&#xD;
          -  Patients with a known history or prior diagnosis of optic neuritis or other&#xD;
             immunologic or inflammatory disease affecting the central nervous system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saar Gill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

